Determination of nucleoside DOT1L inhibitors' residence times by τRAMD simulations
Human epigenetic enzyme disruptor of telomeric silencing 1-like (DOT1L) is a key drug target for treating acute myeloid leukemia. Several nucleoside and non-nucleoside DOT1L inhibitors have been developed to inhibit its histone methyltransferase activity. Non-mechanism-based nucleoside DOT1L inhibit...
Saved in:
Main Authors: | Carlos D. Flores-León (Author), Luis Fernando Colorado-Pablo (Author), Miguel Á. Santos-Contreras (Author), Rodrigo Aguayo-Ortiz (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of Τh1 and Τh2 cytokines in the progression of idiopathic nephrotic syndrome due to focal segmental glomerulosclerosis and minimal change disease
by: Maria Stangou, et al.
Published: (2017) -
Therapeutic drug monitoring of vancomycin by AUCτ-MIC ratio in patients with chronic kidney disease
by: Ahmad Khoei, et al.
Published: (2019) -
Τhe Impact of Training Environmental Educators: Environmental Perceptions and Attitudes of Pre-Primary and Primary School Teachers in Greece
by: Dafni Petkou, et al.
Published: (2021) -
Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
by: Daniel M. Himmel, et al.
Published: (2020) -
Nucleoside Modifications
Published: (2017)